FDA approves pangenotypic drug for Hepatits C The FDA has approved Epclusa, a combination of Sofosbuvir and Velpatasvir as a treatment of all genotypes of Hepatitis C.
The FDA has approved Epclusa, a combination of Sofosbuvir and Velpatasvir as a treatment of all genotypes of Hepatitis C.
